Advanced Cervical Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “Advanced Cervical Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Advanced Cervical Cancer: Overview
Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.
'Advanced Cervical Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Cervical Cancer pipeline landscape is provided which includes the disease overview and Advanced Cervical Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Cervical Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Advanced Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Cervical Cancer Emerging Drugs
Further product details are provided in the report.
Advanced Cervical Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Cervical Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Advanced Cervical Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cervical Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cervical Cancer drugs.
Advanced Cervical Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Advanced Cervical Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Advanced Cervical Cancer: Overview
Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.
'Advanced Cervical Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Cervical Cancer pipeline landscape is provided which includes the disease overview and Advanced Cervical Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Cervical Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cervical Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Cervical Cancer.
This segment of the Advanced Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Cervical Cancer Emerging Drugs
- Durvalumab: AstraZeneca
- Dostarlimab: GlaxoSmithKline
Further product details are provided in the report.
Advanced Cervical Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Cervical Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Cervical Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Advanced Cervical Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cervical Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cervical Cancer drugs.
Advanced Cervical Cancer Report Insights
- Advanced Cervical Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Cervical Cancer drugs?
- How many Advanced Cervical Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Cervical Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Cervical Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Cervical Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- GlaxoSmithKline
- Human Genome Sciences Inc.
- Advaxis
- Bristol-Myers Squibb
- Innovent Biologics
- Hookipa Biotech GmbH
- Shanghai Henlius Biotech
- Biocad
- Genexine, Inc.
- Merck KGaA
- Zeria Pharmaceutical
- ISA Pharmaceuticals
- Agenus Inc.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Vaccibody AS
- Pfizer
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Karyopharm Therapeutics Inc
- NETRIS Pharma
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Xencor, Inc.
- Genmab
- Sotio a.s.
- Andes Biotechnologies
- Rubius Therapeutics
- Durvalumab
- Dostarlimab
- Andes-1537
- RTX-321
- Mapatumumab
- ADXS11-001
- SO-C101
- tisotumab vedotin
- ISA101
- Balstilimab
- XmAb20717
- SG001
- NP137
- Selinexor
- FF-10850
- TQ-B3525
- PF-06939999
- Z-100
- M7824
- VB10.16
- GX-188E
- BCD-100
- Nivolumab
- IBI310
- HLX10
- HB-201
Introduction
Executive Summary
Advanced Cervical Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Durvalumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Serplulimab: Henlix Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
RTX-321: Rubius Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Cervical Cancer Key Companies
Advanced Cervical Cancer Key Products
Advanced Cervical Cancer- Unmet Needs
Advanced Cervical Cancer- Market Drivers and Barriers
Advanced Cervical Cancer- Future Perspectives and Conclusion
Advanced Cervical Cancer Analyst Views
Advanced Cervical Cancer Key Companies
Appendix
Executive Summary
Advanced Cervical Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Durvalumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Serplulimab: Henlix Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
RTX-321: Rubius Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Cervical Cancer Key Companies
Advanced Cervical Cancer Key Products
Advanced Cervical Cancer- Unmet Needs
Advanced Cervical Cancer- Market Drivers and Barriers
Advanced Cervical Cancer- Future Perspectives and Conclusion
Advanced Cervical Cancer Analyst Views
Advanced Cervical Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Advanced Cervical Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Advanced Cervical Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Advanced Cervical Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Advanced Cervical Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
